company background image
SH0 logo

Shionogi DB:SH0 Stock Report

Last Price

€12.80

Market Cap

€11.4b

7D

-1.5%

1Y

-10.7%

Updated

23 Dec, 2024

Data

Company Financials +

Shionogi & Co., Ltd.

DB:SH0 Stock Report

Market Cap: €11.4b

SH0 Stock Overview

Engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. More details

SH0 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth0/6
Past Performance2/6
Financial Health6/6
Dividends5/6

Rewards

Trading at 50.7% below our estimate of its fair value

Pays a reliable dividend of 2.64%

Trading at good value compared to peers and industry

Risk Analysis

No risks detected for SH0 from our risk checks.

My Notes

Capture your thoughts, links and company narrative

Shionogi & Co., Ltd. Competitors

Dermapharm Holding

XTRA:DMP

€2.0b

Merck KGaA

XTRA:MRK

€60.1b

PharmaSGP Holding

XTRA:PSG

€283.0m

Pierrel

DB:2FJ0

€92.8m

Price History & Performance

Summary of share price highs, lows and changes for Shionogi
Historical stock prices
Current Share PriceJP¥12.80
52 Week HighJP¥16.20
52 Week LowJP¥11.67
Beta0.30
1 Month Change3.23%
3 Month Change-3.03%
1 Year Change-10.70%
3 Year Change-39.05%
5 Year Change-29.98%
Change since IPO181.53%

Recent News & Updates

Recent updates

Shareholder Returns

SH0DE PharmaceuticalsDE Market
7D-1.5%-2.2%-2.0%
1Y-10.7%-15.6%6.9%

Return vs Industry: SH0 exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: SH0 underperformed the German Market which returned 6.9% over the past year.

Price Volatility

Is SH0's price volatile compared to industry and market?
SH0 volatility
SH0 Average Weekly Movement6.5%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: SH0 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: SH0's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
18784,959Isao Teshirogiwww.shionogi.com

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19.

Shionogi & Co., Ltd. Fundamentals Summary

How do Shionogi's earnings and revenue compare to its market cap?
SH0 fundamental statistics
Market cap€11.44b
Earnings (TTM)€947.43m
Revenue (TTM)€2.57b

12.1x

P/E Ratio

4.5x

P/S Ratio

Is SH0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SH0 income statement (TTM)
RevenueJP¥418.51b
Cost of RevenueJP¥59.85b
Gross ProfitJP¥358.66b
Other ExpensesJP¥204.09b
EarningsJP¥154.57b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Jan 31, 2025

Earnings per share (EPS)181.70
Gross Margin85.70%
Net Profit Margin36.93%
Debt/Equity Ratio0%

How did SH0 perform over the long term?

See historical performance and comparison

Dividends

2.6%

Current Dividend Yield

31%

Payout Ratio

Does SH0 pay a reliable dividends?

See SH0 dividend history and benchmarks
When do you need to buy SH0 by to receive an upcoming dividend?
Shionogi dividend dates
Ex Dividend DateMar 28 2025
Dividend Pay DateJun 23 2025
Days until Ex dividend95 days
Days until Dividend pay date182 days

Does SH0 pay a reliable dividends?

See SH0 dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:51
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shionogi & Co., Ltd. is covered by 26 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Aaron HoCFRA Equity Research